Overview

Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the use of an oral bisphosphonate (alendronate) in preventing bone loss in postmenopausal women with early breast cancer who are receiving anastrozole therapy, and to determine how long alendronate treatment is needed.
Phase:
Phase 3
Details
Lead Sponsor:
Barwon Health
Collaborator:
AstraZeneca
Treatments:
Alendronate
Anastrozole